Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

Table 4 Prognostic factors for distant disease-free survival: univariate analysis

	N	5-Year DDFS (%) (95 % CI)	HR (95 % CI)	p-value^a
Age
< 35	30	82.6 [68.2–100]	1
≥ 35	726	93.3 [91.2–95.4]	0.5 [0.2–1.3]	0.1223
SBR Grade
1–2	462	96 [94–98]	1
3	285	87.4 [82.9–92.1]	2.8 [1.6–4.9]	0.0002
Pathological tumor size
pT1	391	93.6 [90.9–96.5]	1
pT2	320	92.3 [88.9–95.7]	1.2 [0.7–2]
pT3-T4	36	88.2 [78–99.8]	1.6 [0.6–4.7]	0.6395
PVI
No	558	94.2 [92–96.5]	1
Yes	178	88.8 [83.5–94.5]	2.2 [1.3–4]	0.0042
Hormone receptors
Negative	208	88 [83–93.4]	1
Positive	526	94.7 [92.5–96.9]	0.6 [0.3–1]	0.049
HER2
Negative	507	93.2 [90.5–95.9]	1
Positive	96	95.7 [91–100]	0.9 [0.3–2.2]	0.7719
IHC subtypes
Luminal A	289	96.8 [94.5–99.2]	1
Luminal B/HER2-negative	82	85.5 [76.3–95.8]	4.6 [1.8–11.7]
Luminal B/HER2-positive	58	100 [100–100]	1.2 [0.2–5.5]
HER2	37	89 [77.6–100]	2.9 [0.8–11.1]
Triple-negative	127	89 [82.5–96]	3.3 [1.3–8.2]	0.0059